Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Peter Ludlum
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Beta
- 1.92
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -129.50
Financials
Revenue
$0.00-100.0%Net Income
$-1.04MEBITDA
$-1.05MFree Cash Flow
$-1.11MEPS (diluted)
$-0.29Shares Outstanding (diluted)
3.65M+4818.8%Operating Expenses
$1.05MCash & Debt
$2.17MReturn of Capital
$0.00Revenue by Segment (annual)
$1.65MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-5.16M | $-1.41 |
| 2024 | $7.81M | $-9.56M | $-2.62 |
| 2023 | $7.30M | $-14.12M | $-3.87 |
| 2022 | $6.07M | $-18.84M | $-5.43 |
| 2021 | $5.17M | $-20.17M | $-8.63 |
| 2020 | $12.63M | $-19.31M | $-19.83 |
| 2019 | $7.91M | $-20.60M | $-24.37 |
| 2018 | $153.0K | $-20.56M | $-99.67 |
| 2017 | $335.0K | $-18.06M | $-186.42 |
| 2016 | $835.0K | $-27.84M | $-375.87 |
| 2015 | $1.20M | $-26.17M | $-646.91 |
| 2014 | $352.0K | $-24.14M | $-765.72 |
| 2013 | $653.0K | $-13.31M | $-130.75 |
| 2012 | $0.00 | $-30.0K | $-7.50 |
Valuation
PULMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
90-10.00%Social Signal Score
Mentions (3)
- Newsdefenseworld.net·9d ago·Negative
Pulmatrix, Inc. (NASDAQ:PULM) Stock Short Interest Rises 174.2% Pulmatrix, Inc. (NASDAQ: PULM - Get Free Report) was the recipient of a significant increase in short interest in September. As of September 15th, there was short interest totaling 55,391 shares, an increase of 174.2% from the August 31st total of 20,198 shares. Currently, 1.5% of the company's stock are short sold. Based on an average
View source ↗ - Newsglobenewswire.com·14d ago·Negative
Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria Founder and CEO Kevin Slawin, M.D., to deliver industry keynote on advancing mitochondrial-targeted geropeptide medicine Eos advancing lead candidate MitoXcel™ geropeptide PTC-2105 toward first-in-human studies for sarcopenia and sarcopenic obesity Eos anticipates closing of Pulmatrix, Inc. merger in Q4 subject to customary closing conditions HOUSTON, Sept.
View source ↗ - Newsprnewswire.com·54d ago·Neutral
…related to the announced merger agreement with Eos SENOLYTIX FRAMINGHAM, Mass., Aug. 13, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced its second quarter financial results for 2026 and provided a corporate…
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-2.00 per share
Typical surprise +85.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.29 vs $-2.00beat
Estimates and results for PULM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PULM officers and directors.
- Bought
- $2.4m
- Sold
- —
3 trades
0 trades
- Gillis Stevenbought
- Gillis Stevenbought
- Gillis Stevenbought
97 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PULM.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.